Today: 3 July 2026
Crocs stock slides 6% today — what Wall Street is watching next for CROX
30 December 2025
1 min read

Crocs stock slides 6% today — what Wall Street is watching next for CROX

NEW YORK, December 29, 2025, 23:17 ET — Market closed.

  • Crocs shares fell 6.2% on Monday to $85.94.
  • The stock lagged consumer discretionary peers despite a modestly lower broader market.
  • Traders are eyeing Fed minutes, jobless claims and Crocs’ next earnings update.

Crocs Inc shares closed down 6.2% on Monday at $85.94, giving back early gains and finishing near the day’s lows.

The late-December drop lands as investors reset positions into year-end and start looking ahead to fourth-quarter results across retail and apparel. For Crocs, the focus is on whether demand holds up after the holiday period and whether margins can stay firm as promotions ebb and flow.

The next major checkpoint is Crocs’ quarterly report, expected on Feb. 12, according to Nasdaq. Investors will also be measuring results against the company’s adjusted earnings per share (EPS) guidance — a profit metric that excludes certain one-time items.

U.S. stocks ended lower on Monday, with the S&P 500 down 0.35% and the Nasdaq off 0.5% as big technology names retreated, Reuters reported. “This is (not) the beginning of the end of the tech dominance, it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust, in the same report, which noted Fed minutes and weekly jobless claims are among the week’s key macro events. Reuters

In consumer discretionary, the Select Sector SPDR ETF (XLY) fell about 1%, while Nike and Deckers Outdoor edged higher. Crocs’ decline stood out against that backdrop.

Crocs opened at $91.04 and traded as high as $91.68 before sliding to a session low of $84.88, according to market data. Roughly 2.1 million shares changed hands.

The company’s last earnings update came on Oct. 30, when it reported third-quarter revenue of $996 million, down 6.2% year-on-year, and guided fourth-quarter revenue to be down about 8% versus a year earlier. Crocs also said it expected adjusted EPS of $1.82 to $1.92 and pointed to additional cost savings while continuing share repurchases.

Investors remain sensitive to the split between Crocs’ core brand and HEYDUDE, and to the balance between wholesale and direct-to-consumer (DTC) sales — sales through the company’s own stores and websites — as demand normalizes across the category.

Before Tuesday’s session, the week’s Fed minutes and jobless claims data are likely to set the tone for rate-sensitive parts of the market, especially with liquidity thinning into year-end.

For CROX, traders will be watching technical levels — price points that investors use as rough markers for where buying or selling has tended to show up. After Monday’s slide, the $85 area is back on the radar as near-term support, with the $90-$92 zone a key hurdle after the day’s early peak.

Absent fresh company news, the next meaningful catalyst remains the expected Feb. 12 earnings report, when investors will look for an update on demand, margins and management’s cost actions. Until then, CROX is likely to trade with broader consumer discretionary sentiment and any shifts in rate expectations.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Raffles Medical Group (SGX:BSL) jumps after AI brain imaging partnership, valuation gap in focus
    July 3, 2026, 12:51 PM EDT. Raffles Medical Group (SGX:BSL) moved after a new partnership with Neurophet to provide AI software for brain MRI scans tied to neurodegenerative diseases. Shares traded at SGD0.93. The one-year shareholder return sits at -5.04%; year-to-date, the stock is down 8.82%. The P/E ratio is 24.3 times, which is below the peer group average of 29.4 but higher than the Asian healthcare industry's 19.9 and just above a calculated fair P/E of 23.8. A DCF model puts value 38.9% higher at SGD1.52, pointing to possible undervaluation. The market is weighing those potential gains against earnings risks and regulatory uncertainty in Singapore and Greater China.
Luxury brands’ Instagram Reels views jump 234% as TikTok momentum fades, data show
Previous Story

Luxury brands’ Instagram Reels views jump 234% as TikTok momentum fades, data show

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake
Next Story

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake

Go toTop